Cools Tanne L, Struyfs Caroline, Drijfhout Jan W, Kucharíková Soňa, Lobo Romero Celia, Van Dijck Patrick, Ramada Marcelo H S, Bloch Carlos, Cammue Bruno P A, Thevissen Karin
Centre of Microbial and Plant Genetics, KU Leuven, Leuven, Belgium.
Department of Plant Systems Biology, VIB, Ghent, Belgium.
Front Microbiol. 2017 Oct 20;8:2051. doi: 10.3389/fmicb.2017.02051. eCollection 2017.
Public health problems are associated with device-associated biofilm infections, with being the major fungal pathogen. We previously identified potent antibiofilm combination treatment in which the antifungal plant defensin HsAFP1 is co-administered with caspofungin, the preferred antimycotic to treat such infections. In this study, we identified the smallest linear HsAFP1-derived peptide that acts synergistically with caspofungin or anidulafungin against as HsLin06_18, a 19-mer peptide derived from the C-terminal part of HsAFP1. The [caspofungin + HsLin06_18] combination significantly reduced biofilm formation of and on catheters, as well as biofilm formation of a caspofungin-resistant strain. The [caspofungin + HsLin06_18] combination was not cytotoxic and reduced biofilm formation of using a subcutaneous rat catheter model, as compared to control treatment. Mode of action research on the [caspofungin + HsLin06_18] combination pointed to caspofungin-facilitated HsLin06_18 internalization and immediate membrane permeabilization. All these findings point to broad-spectrum antibiofilm activity of a combination of HsLin06_18 and caspofungin.
公共卫生问题与器械相关的生物膜感染有关,其中 是主要的真菌病原体。我们之前确定了一种有效的抗生物膜联合治疗方法,即抗真菌植物防御素HsAFP1与卡泊芬净联合使用,卡泊芬净是治疗此类感染的首选抗真菌药物。在本研究中,我们确定了与卡泊芬净或阿尼芬净协同作用对抗 的最小线性HsAFP1衍生肽为HsLin06_18,这是一种源自HsAFP1 C末端部分的19肽。[卡泊芬净 + HsLin06_18]组合显著减少了 和 在导管上的生物膜形成,以及卡泊芬净耐药 菌株的生物膜形成。与对照治疗相比,[卡泊芬净 + HsLin06_18]组合在皮下大鼠导管模型中无细胞毒性,并减少了 的生物膜形成。对[卡泊芬净 + HsLin06_18]组合的作用方式研究表明,卡泊芬净促进了HsLin06_18的内化并立即导致膜通透性增加。所有这些发现都表明HsLin06_18和卡泊芬净组合具有广谱抗生物膜活性。